Anti-leukemia activity of human macrophages involves the generation of nitric oxide (NO) derivatives. However, leukemic transformation may involve mechanisms that rescue cells from NO-mediated apoptosis. In the present work, we analyzed the effects of exogenous NO on the proliferation of BCR-ABL 
Introduction
NO is a messenger molecule with complex biological activities including inflammation, immunoregulation, vasodilatation, and neurotransmission. [1] [2] [3] [4] NO is synthesized enzymatically from L-arginine by at least three different NO synthases (NOS). The endothelial and the neuronal isoforms are constitutively expressed. The third isoform, NOS-II, has to be induced with various stimuli and is able to synthesize large amounts of NO, which can lead to the inhibition of T cell proliferation, tumoricidal activity, suppression of cellular protein synthesis, oxidative damage, and apoptosis. 3, 4 NOmediated DNA damage induces apoptotic cell death in leukemia cells after the induction of the endogenous NOS-II or by the application of an exogenous NO. [5] [6] [7] [8] [9] In contrast, some leukemia cell lines express or could be induced to express NOS-II without any inhibitory effect on their growth. 10, 11 This implies that leukemic transformation enables cells to counteract NO-mediated cytotoxicity or that NO is no longer toxic for these leukemia cells. It has also been shown that in some tissues, including leukemia cells, NO synthesis was even cytoprotective. [12] [13] [14] [15] pro-apoptotic effect of NO by applying various exogenous NO formulations. These data led us to analyze the role of iron during NO-mediated cytotoxicity.
For the past decades, iron has been shown to favor neoplasic cell growth and to display carcinogenic activity. 16, 17 This is explained by the catalytic effect of iron on the formation of hydroxyl radicals, suppression of the activity of host defence cells, and promotion of tumor cell multiplication. 16 Primary neoplasms develop at body sites of excessive iron deposits. 18, 19 The invaded host attempts to withhold iron from the transformed cells via sequestration of the metal in newly formed ferritin. 16 The host also endeavors to withdraw the metal from tumor cells via macrophage synthesis of NO. 20, 21 In the BCR-ABL + leukemia K562 cell line, 10, 22, 23 reports have shown the high affinity between NO and Fe-containing proteins, a phenomenon involved in the regulation of ␥-globin and transferrin receptor expression. In various BCR-ABL + cell lines, the present study indicates that the pro-leukemia effect of iron may be in part related to its ability to rescue cells from NO-mediated apoptosis.
Materials and methods

Chemicals
NO-releasing compounds used in this study are SNAP (S-nitroso-N-acetyl-penicillamine), SIN-1 (3-morpholinosydnonimine), GEA (GEA5024, 1,2,3,4-Oxatriazolium, 5-amino-3-(3-chloro-2-methylphenyl)-, chloride) (Alexis, Coger, Paris, France), and SNP (Sodium nitroprusside; Sigma-Aldrich, Saint Quentin Fallavier, France). SIN-1 was also used in therapeutic formulation Linsidomine (Corvasal; Hoechst Hondé, Paris, France). In the presence of cells, in vitro half-life of the above mentioned NO-releasing compounds were about 1 h, 18 h, 4 h and 24 h for SNAP, SNP, SIN-1 and GEA, respectively. Chemicals were put in solutions and prepared immediately before use. Potassium ferricyanide, potassium ferrocyanide, sodium cyanide, ferric citrate, ferric and ferrous ammonium sulfate were purchased from Sigma-Aldrich. As iron chelator, we used deferoxamine mesylate from SigmaAldrich or Desferal from Novartis Pharma (Rueil-Malmaison, France).
Normal and leukemia cells
The human BCR-ABL + leukemia cell lines K562, KCL22, KYO and LAMA84 were a kind gift of F-X Mahon, Bordeaux University, France. Cell lines were cultured in RPMI-1640 supplemented with 10% fetal calf serum (FCS), penicillin 100 U/ml, streptomycin 100 g/ml, and 1 mM L-glutamine (all from Gibco-BRL, Cergy-Pontoise, France 
Cell proliferation
Cells were seeded in 24-well culture plates at 50 000 cells/ml/well. For normal PBL, phytohemagglutinin (PHA, 5 g/ml; Murex Biotech Limited, Dartford, UK) was added to induce cell proliferation. CD34 + cells were cultured in medium supplemented with interleukin-1 (IL-1, 500 U/ml), IL-3 (10 ng/ml), and stem cell factor (SCF) (10 ng/ml) (a kind gift from Amgen, Cambridge, UK). The various reagents were added simultaneously as described in Results. After incubation, cells were harvested, washed, and counted with trypan blue exclusion. CD34
+ cells (10 000/ml) were also plated in 35 mm culture dishes (Falcon, Subra, Toulouse, France) in medium containing 30% FCS, 1% bovine serum albumin, 10 −4 M 2-mercaptoethanol, 2 mM L-glutamine and 1% methylcellulose containing CFU-inducing cytokines (MethoCult GF + H4435; Stem Cell Technologies, Meylan, France). The frequency of CFU-GM (Ͼ20 cells) was enumerated on day 14.
Cell cycle and apoptosis
Cell cycle was analyzed as described elsewhere. 24 Cells were washed in phosphate buffer solution (PBS) containing 1% bovine serum albumin. Pellets were then treated with 200 l lysis solution (calcium-and magnesium-free PBS, 0.5% Nonidet-P40, 20 g/ml propidium iodide, 0.2 mg/ml RNAse A, 0.5 mM EDTA, pH 7.2) (all from Sigma-Aldrich) at room temperature, in the dark for 20 min prior to measurement. DNA analysis was performed using the System II Coulter program (XL Coulter Instrument, Coultronics, Margency, France). Activation of caspases was evaluated through DEVDase stimulation and performed as detailed elsewhere. 25 Briefly, 7.5 × 10 4 cells were cultured in triplicates into 96-well plates in the presence or absence of SIN-1. After 3 days incubation, the plates were centrifuged at 1500 r.p.m. for 5 min, culture supernatant removed, and the cells were resuspended in 50 l of a pH 7.4 buffer containing 10 mM Hepes, 5 mM DTT, 2 mM EDTA, 0.02% saponine, 1 mM PMSF, 10 g/ml pepstatin A, 10 g/ml leupeptin and 72 M fluorogenic substrate Ac-DEVD aminomethylcoumarin (UBI Euromedex, Souffelweyerssheim, France). Development of the reaction was read on an automatic spectrofluorometer (Victor 2 Multilabel Counter; Wallac & Perkin Elmer, Akron, OH, USA), at 37°C using exc = 380 nm and em = 480 nm. Following this, 200 l of a 15 g/ml propidium iodide solution were added to each well and other measures were applied at exc = 360 nm and em = 600 nm, to evaluate cell proliferation. The caspase-3 activity was calculated for 10 5 cells after taking into account the degree of cell proliferation. To measure apoptosis, externalization of membrane phosphatidylserine was analyzed using annexin V-FITC and propidium iodide kit (Immunotech, Marseille, France).
Leukemia
Intracellular iron quantification
Intracellular total and ferrous (Fe 2+ ) iron levels were measured using a standard analytic procedure as detailed elsewhere. 26 Ferric iron (Fe 3+ ) levels were obtained following subtraction of Fe 2+ levels from total iron values. Iron levels were shown as nmol per mg protein.
Statistical analysis
Cells were cultured in duplicates or triplicates; each repeated two to five times for each assay. Statistical analysis was performed using Systat. For better comparison of cell growth, some results were expressed as the percentage of viable cells compared to the number of cells incubated in medium alone.
Results
NO donors differ in their anti-proliferation effects on myeloid leukemia cells
Various NO-releasing compounds were tested for their effects on the proliferation of BCR-ABL + leukemia cell lines, as compared to PHA-activated normal PBL. SNAP, SNP, GEA and SIN-1 were used as NO-releasing compounds. The breakdown of these molecules and their ability to release NO during cultures was attested through the generation of nitrites in cell supernatants (data not shown). As shown in Figure 1 , the
Figure 1
Anti-proliferation activity of NO-releasing compounds on normal and leukemia cells. Leukemia K562 cells or PHA-activated normal human PBL were incubated (50 000/ml) for 4 days with various indicated doses of chemical NO. Results show mean numbers of viable cells following cell treatment, from three to six different experiments (s.e.m. Ͻ23%).
proliferation of leukemia cells was variably affected by the above NO-releasing compounds. Leukemia cells were less sensitive to SNAP than normal cells, whereas SIN-1 displayed more anti-proliferative effect in leukemia cells. GEA was highly inhibitory for both normal and leukemia cells. SNP inhibited normal cell growth but failed to significantly decrease the proliferation of leukemia cells (see below). These data suggested that SIN-1 and GEA displayed significant antileukemia effect, compared to SNAP. To confirm these data, SIN-1 and GEA were added to the cultures of four distinct BCR-ABL + cell lines: KCLL22, LAMA84, KYO and K562. Figure 2 clearly shows that all CML-derived cell lines were sensitive to the inhibitory effect of both compounds (P Ͻ 0.001).
SIN-1 and GEA were also tested for their effects on the growth of purified CD34
+ leukemia cells from untreated CML patients. Figure 3a shows that SIN-1 and GEA decreased the proliferation of CML precursor cells in liquid cultures at a dose-dependent manner. In semi-solid cultures, SIN-1 has a low (P Ͻ 0.02) inhibitory effect on the number of leukemia CFU, but it decreased significantly (P Ͻ 0.002) the number of cells per colony (Figure 3b ). Similar data were obtained with GEA (not shown).
Effects of NO on cellular signaling and apoptosis in leukemia cells
The ability of NO to induce apoptosis and to modulate cell cycle was investigated in both leukemia cell lines and CD34 + patient cells. As GEA showed high toxicity in normal cells, and because of the availability of a therapeutic form of SIN-1 (Linsidomine; Corvasal), 27 the latter compound has been selected for further studies. Data in Figure 4a indicate that SIN-1 induced a dose-dependent increase in phosphatidylserine externalization, a marker of membrane features of apoptosis. This was confirmed by the appearance of a sub-G1 DNA peak (Figure 4b ) without evidence for specific nuclear cell cycle modifications. As suggested in other leukemia models, 9 induction of DEVDase activity was also observed in BCR-ABL + cells incubated with SIN-1 (Figure 4c ). Therefore, in addition to the inhibition of cell growth, NO induced a significant induction of caspase activity and apoptosis in leukemia cells. 
Iron protects leukemia cells from NO
In contrast to normal cells, BCR-ABL
+ leukemia cells were resistant to SNP addition (Figure 1 ). In addition to NO release, SNP contains ferric sodium cyanide, making it different from other NO-releasing compounds. 28 The role of non-NO, FeCN or NaCN moiety of this molecule was then investigated during leukemia cell proliferation. The addition of up to 500 M potassium ferricyanide (Fe 3+ CN), ferrocyanide (Fe 2+ CN) or NaCN alone to leukemia cells did not affect their growth ( Figure 5 ). We then investigated the effect of these molecules on NOmediated growth inhibition. Addition of NaCN to exogenous NO (SIN-1) did not modify leukemia cell growth. In contrast, simultaneous addition of only 2 M FeCN, another molecular moiety of SNP, to SIN-1 significantly rescued leukemia cell growth ( Figure 5 ). As NaCN did not affect cell proliferation, we then asked if the Fe moiety of FeCN was a leukemia cell rescue factor. Leukemia cells were then incubated with another ferrous or ferric compound in the presence or the absence of SIN-1. Data in Figure 5 indicate that exogenous iron supplementation significantly (P Ͻ 0.002) rescued leukemia cells from the anti-proliferation effect of SIN- SIN-1 (Figure 6 ) or SNAP (data not shown). Exogenous iron also protected CML patient- derived CD34 + cells from SIN-1-induced inhibition of sub-G1 DNA peak induction and apoptosis (Figure 7a ). Iron also reversed NO-induced activation of intracellular caspases in leukemia cells (Figure 7b ). These data clearly indicate that iron supplementation to BCR-ABL + cells, even at 1-2 log lower concentrations than NO, protected them from apoptosis. 8a indicates that SIN-1 induced a rapid decrease of intracellular iron levels in leukemia cells, an effect reversed through the simultaneous addition of iron to these cultures. The decrease of intracellular total or ferric iron (Ͼ80% of total iron, range 82-91) levels in the presence of SIN-1 always corroborated with lower leukemia cell recovery, whereas stabilization of Fe levels correlated with leukemia cell protection (Figure 8b ). We then compared the sensitivity of leukemia cells to iron chelation to that observed with normal PBL. Using DFX for iron chelation, results in Figure 9 indicate that the proliferation of BCR-ABL + leukemia cells was more sensitive than normal hemopoietic cells to the inhibitory effect of iron chelation by DFX (P Ͻ 0.001) (Figure 9 ). This effect is dose-dependent and may be reversed through the supplementation of exogenous iron to leukemia cells (Figure 9 ).
NO induced a rapid intracellular iron depletion in leukemia cells
Discussion
The expression of functional NOS-II in different human cell types including leukemia cells 11, 13, 29, 30 investigated the role of NO as a member of anti-leukemia tools of macrophages. 3, 31 The present study indicates that BCR-ABL + myeloid leukemia cells remained sensitive to the anti-proliferation property of exogenous NO. Leukemia cell responses depended upon the chemical formulation of exogenous NO and were distinct from normal cell sensitivity to the same compounds. Among NO donors, GEA was highly toxic for both normal and leukemia cells, whereas SIN-1 27 had higher anti-proliferation effects in leukemia cells than in normal PBL. In contrast to GEA or SNAP, SIN-1 may generate peroxynitrites, 27 potent proapoptotic compounds. 9 In addition to growth inhibition, NO promoted leukemia cell apoptosis, as evidenced through membrane phosphatidylserine externalization, DNA fragmentation, and the activation of DEVDases. These results indicate that appropriate NO formulations have potent anti-proliferative properties in BCR-ABL + leukemia cells. In contrast to other NO donors, SNP was unable to display any anti-leukemia activity in BCR-ABL + cells, whereas it clearly inhibited the growth of normal PBL. This compound contains ferric sodium cyanide that distinguishes it from the other NO-releasing compounds. 28 Following the analysis of molecular composition of SNP, we revealed that iron, present in FeCN form, had the ability to reverse NO-mediated antileukemia activity. Of interest, this was obtained with 1-2 logs less than the NO donors added to leukemia cells. Owing to the presence of iron in SNP, our finding may explain the failure of this compound to display leukemia growth inhibition. Through the use of various iron containing compounds, our results clearly showed the ability of iron radicals to rescue leukemia cells from the anti-leukemia activity of NO. Similarly to the present study, Richardson et al 22 did not observe growth inhibition with SNP, whereas SIN-1 and SNAP (1 mM from each) decreased cell proliferation. SNP decreased RNAbinding activity of iron-responsive element-binding protein, 22 a factor necessary for the regulation of ferritin mRNA translation and transferrin receptor mRNA stability. 32 In C6 glioma cells, a recent report 33 has shown that SNP prevented cell death through the stimulation by iron ions of the activity of Na + -Ca + exchanger. Iron affinity to NO may lead to NO capture and consequent cell protection from the pro-apoptotic effect of NO. This is unlikely in BCR-ABL + cells, as only 1-2 log lower equimolar levels of iron were required to rescue leukemia cells. NO may also lead to intracellular Fe loss, which is by itself cytotoxic for tumor cells. This is likely to be the principal mechanism of NO in BCR-ABL + cells because, as observed with DFX, rapid decreases in intracellular iron levels induced apoptotic cell death in these cells. Accordingly, increased iron levels in leukemia cells or iron supplementation may protect these cells from apoptosis. An early study suggested a role for iron depletion during tumor cell cytotoxicity induced by activated macrophages. 34 Iron chelators have been shown to induce apoptosis in a promyelocytic cell line, HL-60, 35 and to increase AraC-mediated apoptosis of myeloid HL60 and U937 cells. 36 The relationship between NO and other established treat-
Leukemia
Figure 9
Increased mortality of leukemia cells following iron deprivation. Dose-dependent effect of deferoxamine (DFX) on in vitro survival of leukemia K562 cells compared to PHA-induced normal PBL. Addition of exogenous iron (20 M SO4Fe
2+
, shaded bar) partially reversed DFX effect on leukemia cells. Representative data from one normal donor and K562 cells following 3 day incubation, out of three distinct experiments. ment protocols in CML remains to be investigated. IFN-␣, one of the therapeutic tools in CML, has been shown to induce the transcription of NOS-II gene and promote NO generation from human hemopoietic cells. 37 In vivo, treatment of hepatitis patients with IFN-␣ clearly correlated with an in vivo enhancement of iNOS expression. 37 Of particular interest, patients with high iron levels were less responsive to such IFN-␣ treatment, compared to those with low in vivo iron concentrations. 38, 39 Kim et al 40 have recently suggested that hepatic cell content of non-heme iron determined whether cytotoxic levels of NO resulted in apoptosis vs necrosis. Regarding the present work, iron availability may therefore rescue hepatitis virus-infected cells from NO-mediated killing. More recently, we have shown that SNAP, a NO-releasing compound with potent pro-apoptotic activity in human epitheliod cancer cells, induced a rapid iron chelation in cancer cells. 41 Together these data suggest that increases in intracellular iron levels may contribute to CML patient cell rescue from IFN-␣ or other therapies. 42 Investigation of in vivo heme and non-heme iron levels in CML patients, and their relation to drug resistance may help to answer this issue. The present study may help to define new therapeutic approaches as pharmaceutical methods for depriving tumor cells of iron are being developed in experimental and clinical protocols, 43, 44 and may assist in prevention and management of leukemia.
